I'm LongbridgeAI, I can summarize articles.Ascendiant Capital maintained a Buy rating on Aytu BioPharma with a $15 price target, implying a 581.8% upside from the September 29 close of $2.20. The firm cited strong fiscal Q4 results exceeding estimates and consensus, with revenue reaching $16.1 million (up 6% YoY). Additionally, the launch of EXXUA targets the $22 billion U.S. market for major depressive disorder, positioning the company for significant growth.
Ascendiant Capital maintained their Buy rating on Aytu BioPharma's stock with a price target of $15.00.
The price target implies an upside of 581.8% from the Sep 29 close of $2.20.
Key takeaways from the analyst note
Strong Financial Performance: Aytu BioPharma recently reported fiscal Q4 results that exceeded both internal estimates and consensus, with a revenue of $16.1 million, marking a 6% year-over-year increase. This positive financial performance supports investor confidence in the company's growth trajectory.
Significant Market Opportunity: The launch of EXXUA is targeting the substantial $22 billion U.S. prescription market for major depressive disorder (MDD), addressing a critical need for effective treatments with fewer side effects. This positions Aytu BioPharma for strong future growth and potential market leadership.
Explore more price target data and ratings for Aytu BioPharma on the .